Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21638
Title: | Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat | Authors: | Sedel, Frédéric Chabrol, Brigitte Audoin, Bertrand Kaphan, Elsa Tranchant, Christine BURZYKOWSKI, Tomasz Tourbah, Ayman Vanier, Marie T. Galanaud, Damien |
Issue Date: | 2016 | Publisher: | SPRINGER HEIDELBERG | Source: | JOURNAL OF NEUROLOGY, 263 (5), p. 927-936 | Abstract: | Niemann-Pick disease type C (NP-C) is a fatal progressive neurolipidosis involving neuronal storage of cholesterol and gangliosides. Miglustat, an inhibitor of glycosphingolipid synthesis, has been approved to treat neurological manifestations in adults and children with NP-C. This open-label observational study in adults with confirmed NP-C evaluated the efficacy of miglustat (200 mg t.i.d.) based on composite functional disability (CFD) scores and brain proton magnetic resonance spectroscopy (H-MRS) measurement of choline (Cho)/N-acetyl aspartate (NAA) ratio in the centrum ovale. Overall, 16 patients were included and received miglustat for a mean period of 30.6 months: 12 continued on miglustat throughout follow up, and 4 discontinued miglustat because of adverse effects (n = 2) or perceived lack of efficacy (n = 2). In the 'continued' subgroup, the mean (SD) annual progression of CFD scores decreased from 0.75 (0.94) before treatment to 0.29 (1.29) during the period between miglustat initiation and last follow-up. In the discontinued subgroup, CFD progression increased from 0.48 (0.44) pre-treatment to 1.49 (1.31) at last follow up (off treatment). Mean (SD) Cho/NAA ratio [normal level 0.48 (0.076)] decreased during miglustat treatment in the continued subgroup: 0.64 (0.12) at baseline (miglustat initiation), 0.59 (0.17) at 12-month follow up, and 0.48 (0.09) at 24-month follow up. Cho/NAA ratio remained relatively stable in the discontinued subgroup: 0.57 (0.15), 0.53 (0.04) and 0.55 (0.09), respectively. In conclusion, H-MRS Cho/NAA ratio might serve as an objective, quantitative neurological marker of brain dysfunction in NP-C, allowing longitudinal analysis of the therapeutic effect of miglustat. | Notes: | [Sedel, Frederic] Salpetriere Hosp, AP HP, Dept Neurol, Federat Nervous Syst Dis, 47 Blvd Hop, F-75651 Paris 13, France. [Sedel, Frederic] Univ Paris 06, Neurometab Unit & Reference Ctr Lysosomal Dis, GRC13UPMC, Salpetriere Hosp,AP HP, Paris, France. [Chabrol, Brigitte] CHU Marseille, La Timone Hosp, Dept Pediat, Marseille, France. [Audoin, Bertrand] Aix Marseille Univ, Dept Neurol, CNRS, Div Clin Neurosci,CRMBM UMR 7339,Timone Hosp,AP H, Marseille, France. [Kaphan, Elsa] CHU Timone, Dept Neurol, Div Clin Neurosci, AP HM, Marseille, France. [Tranchant, Christine] CHU Hautepierre, Dept Neurol, Strasbourg, France. [Tranchant, Christine] FMTS, Strasbourg, France. [Burzykowski, Tomasz] Int Inst Drug Dev, Louvain, Belgium. [Burzykowski, Tomasz] Hasselt Univ, Hasselt, Belgium. [Tourbah, Ayman] Univ Paris 08, Dept Neurol, Cent Univ Hosp, Fac Med Reims URCA, St Denis, France. [Tourbah, Ayman] Univ Paris 08, EA 2027, St Denis, France. [Vanier, Marie T.] INSERM, U820, F-69008 Lyon, France. [Galanaud, Damien] Univ Paris 06, Dept Neuroradiol, Paris, France. | Keywords: | Niemann–Pick disease type C; Miglustat; magnetic resonance spectroscopy; substrate reduction therapy;Niemann-Pick disease type C; Miglustat; Magnetic resonance spectroscopy; Substrate reduction therapy | Document URI: | http://hdl.handle.net/1942/21638 | ISSN: | 0340-5354 | e-ISSN: | 1432-1459 | DOI: | 10.1007/s00415-016-8051-1 | ISI #: | 000376141000011 | Rights: | © The Author(s) 2016. This article is published with open access at Springerlink.com | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2017 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art%3A10.1007%2Fs00415-016-8051-1.pdf Restricted Access | Published version | 684.39 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
14
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
17
checked on Aug 11, 2024
Page view(s)
52
checked on Sep 7, 2022
Download(s)
48
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.